26 results
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
9 May 24
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
4:10pm
Society of Retina Specialists (ASRS) Annual Scientific Meeting being held in Stockholm, Sweden from July 17 - 20, 2024.
Preliminary Ixo-vec LUNA … Trial Data at Macula Society 2024:
◦In February 2024, we announced positive preliminary efficacy and safety data from the ongoing LUNA Phase 2 trial
8-K
EX-99.1
ADVM
Adverum Biotechnologies Inc
18 Mar 24
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
4:08pm
Updates
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity … Biotechnologies. “We were pleased to present at Macula Society preliminary data from our ongoing LUNA Phase 2 trial of Ixo-vec, which demonstrated potentially
8-K
EX-99.1
r2w bzil50
9 Nov 23
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
4:07pm
8-K
EX-99.1
ei2visy
11 May 23
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
4:10pm
PRE 14A
35jiy9cxt76qt
14 Apr 23
Preliminary proxy
6:03am
8-K
EX-99.1
sbum2l5qnn
30 Mar 23
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
4:09pm
8-K
EX-99.1
e5s6kqzmt35 xrpgvg
10 Nov 22
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
4:14pm
8-K
EX-99.1
n1jpgkuz2pb1i57 ql3
11 Aug 22
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
jgiqek 14juxz0ea
12 May 22
Adverum Biotechnologies Reports First Quarter 2022 Financial Results
4:14pm
8-K
EX-99.1
da8mcz
4 Nov 21
Adverum Reports Third Quarter 2021 Results
4:12pm
8-K
EX-99.1
9xpr9w bujlt9pd6vywm
12 Sep 19
Adverum Biotechnologies Reports Positive24-Week Data from
6:05am